
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Eloctate | Antihemophilic Factor (Recombinant), Fc Fusion protein | Bioverativ | A-125487 RX | 2014-06-06 | 10 products |
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Jivi | Antihemophilic factor (recombinant), PEGylated-aucl | Bayer | A-125661 RX | 2018-08-29 | 4 products |
| Jivi | Antihemophilic factor (recombinant), PEGylated-aucl | Bayer | N-125661 RX | 2024-12-02 | 1 products |
| Adynovate | Antihemophilic Factor (Recombinant), PEGylated | Takeda | A-125566 RX | 2015-11-13 | 7 products |
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Afstyla | Antihemophilic Factor (Recombinant), Single Chain | CSL Behring | A-125591 RX | 2016-05-25 | 7 products |
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Esperoct | Antihemophilic Factor (Recombinant), GlycoPEGylated-exei | Novo Nordisk | A-125671 RX | 2019-02-19 | 5 products |
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| ALTUVIIIO | antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl | Bioverativ | N-125771 RX | 2023-02-22 | 7 products |
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Humate-P | Antihemophilic Factor/von Willebrand Factor Complex (Human) | CSL Behring | A-103960 RX | 2000-04-11 | 3 products |
| Alphanate | Antihemophilic Factor/von Willebrand Factor Complex (Human) | Grifols | A-102475 RX | 1978-08-15 | 5 products |
Brand Name | Status | Last Update |
|---|---|---|
| alphanate | Biologic Licensing Application | 2010-10-07 |
| altuviiio | Biologic Licensing Application | 2025-03-11 |
| hemofil m | Biologic Licensing Application | 2011-03-15 |
| humate-p | Biologic Licensing Application | 2010-01-14 |
| recombinate | Export only | 2010-05-26 |
| von willebrand factor/coagulation factor viii complex (human) | Biologic Licensing Application | 2010-08-20 |
| xyntha | Biologic Licensing Application | 2011-01-13 |
Code | Description |
|---|---|
| J7180 | Injection, factor xiii (antihemophilic factor, human), 1 i.u. |
| J7182 | Injection, factor viii, (antihemophilic factor, recombinant), (novoeight), per iu |
| J7185 | Injection, factor viii (antihemophilic factor, recombinant) (xyntha), per i.u. |
| J7186 | Injection, antihemophilic factor viii/von willebrand factor complex (human), per factor viii i.u. |
| J7188 | Injection, factor viii (antihemophilic factor, recombinant), (obizur), per i.u. |
| J7189 | Factor viia (antihemophilic factor, recombinant), (novoseven rt), 1 microgram |
| J7190 | Factor viii (antihemophilic factor, human) per i.u. |
| J7191 | Factor viii (antihemophilic factor (porcine)), per i.u. |
| J7192 | Factor viii (antihemophilic factor, recombinant) per i.u., not otherwise specified |
| J7193 | Factor ix (antihemophilic factor, purified, non-recombinant) per i.u. |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophilia a | D006467 | EFO_0007267 | D66 | 66 | 61 | 133 | 68 | 192 | 486 |
| Hemophilia b | D002836 | — | D67 | 8 | 9 | 18 | 4 | 25 | 59 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 5 | 2 | 12 | 3 | 15 | 35 |
| Hemostatic disorders | D020141 | — | — | 5 | 3 | 8 | 3 | 11 | 28 |
| Von willebrand diseases | D014842 | EFO_0003910 | D68.0 | 2 | 3 | 14 | 4 | 4 | 26 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 4 | 3 | 11 | 18 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 2 | 2 | 3 | 2 | 5 | 12 |
| Coagulation protein disorders | D020147 | — | — | 1 | 1 | 4 | 1 | 3 | 9 |
| Inherited blood coagulation disorders | D025861 | — | — | 1 | 1 | 2 | 1 | 3 | 7 |
| Joint diseases | D007592 | — | M12.9 | — | — | — | 2 | 5 | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhagic disorders | D006474 | — | D69.9 | 1 | 1 | 3 | — | 4 | 8 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | 1 | 1 | 2 | — | 2 | 5 |
| Type 3 von willebrand disease | D056729 | Orphanet_166096 | D68.03 | 2 | — | 1 | — | 2 | 5 |
| X-linked genetic diseases | D040181 | — | — | 1 | 1 | 1 | — | 1 | 3 |
| Bone diseases | D001847 | — | M89.9 | — | — | 1 | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | 1 | — | — | 1 |
| Aids-related complex | D000386 | EFO_0007137 | B20 | — | — | 1 | — | — | 1 |
| Sexual behavior | D012725 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | 1 | — | — | — | 5 |
| Genetic therapy | D015316 | — | — | 2 | 2 | — | — | 1 | 3 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 1 | — | — | — | 1 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | — | 1 | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | — | — | 1 |
| Dependovirus | D000229 | — | — | 1 | 1 | — | — | — | 1 |
| Gene transfer techniques | D018014 | — | — | 1 | 1 | — | — | — | 1 |
| Hemostasis | D006487 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Factor vii deficiency | D005168 | — | D68.2 | 2 | — | — | — | — | 2 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | — | — | — | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | — | 3 | 3 |
| Sclerosis | D012598 | — | — | — | — | — | — | 3 | 3 |
| Motor activity | D009043 | EFO_0003940 | — | — | — | — | — | 3 | 3 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | — | 2 | 2 |
| Thrombosis | D013927 | — | — | — | — | — | — | 2 | 2 |
| Infertility | D007246 | EFO_0000545 | — | — | — | — | — | 2 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Seroma | D049291 | — | — | — | — | — | — | 1 | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | — | — | 1 | 1 |
| Replacement arthroplasty | D019643 | — | — | — | — | — | — | 1 | 1 |
| Drug common name | Antihemophilic factor |
| INN | — |
| Description | Alphanate (antihemophilic factor) is a protein pharmaceutical. It is a lyophilized concentrate of Factor VIII (FVIII; AHF) and von Willebrand Factor (VWF). |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | >4KI5:C|MURINE MONOCLONAL 3E6 FAB HEAVY CHAIN
QIQLVQSGPELKKPGKTVKISCKASDYTFTDYSLHWVKQAPGKGLKWMGWINTETGDPAYADDFKGRFAFSLETSVRTAY
LQINNLKNEDTAIYFCAREDDGLASWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSG
SLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPA
>4KI5:D|MURINE MONOCLONAL 3E6 FAB LIGHT CHAIN
QIVLTQSPAIMSASPGEKVTMTCSASSTVSYMYWYQQKPGSSPRFLISDTSNLASGVPVRFSGSGSGTSYSLTISRIEAE
DAATYYCQHWSSYPLTFGGGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLN
SWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
>4KI5:E|MURINE MONOCLONAL G99 FAB HEAVY CHAIN
QVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWVKQRPGHGLEWIGEILPGSGSTNYNERFKGKASFTADSSSNTAY
MQLSSLTSEDSAVYYCTRTSYYFGSSYDFDVWGAGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVT
LTWNSGSLSSGVHTFPALLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGP
>4KI5:F|MURINE MONOCLONAL G99 FAB LIGHT CHAIN
DIQMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYAASTLDSSVPKRFSGSRSGSDYSLTISSLDS
EDFAVYYCLQYASYPYTFGGGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVL
NSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
>4KI5:M|Coagulation factor VIII
MGSSHHHHHHSSGLVPRGSHMLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEW
LQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIH
PQSWVHQIALRMEVLGCEAQDLY |














